Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference
NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the 2020 H.C. Wainwright Global Investment Conference on September 16, 2020:
Presentation Time: 3:00 p.m. ET
A live webcast of the presentation can be accessed by visiting ‘News & Events’ in the ‘Investors & News’ section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the conference.
The Company’s corporate presentation is posted to its website in the ‘Investors & News’ section under ‘News & Events’.
About Trevi Thrapeutics, Inc.
Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.
Millimeter Wave: The Need for Speed
How to Strategically Leverage New Connectivity Options